文献速递浆细胞疾病

克拉霉素、泊马度胺和地塞米松治疗复发或难治性多发性骨髓瘤的2期研究

Phase 2 study of clarithromycin, pomalidomide, and dexamethasone in relapsed or refractory multiple myeloma.
PubMed 文献 · Blood Adv · 2019-01-01

该2期试验评估克拉霉素、泊马度胺和地塞米松(ClaPd)方案治疗既往来那度胺暴露的复发或难治性多发性骨髓瘤(RRMM)的安全性和有效性。120例患者接受ClaPd方案治疗,总缓解率(ORR)为60%,23%达到至少非常好的部分缓解,中位无进展生存期(PFS)为7.7个月,中位总生存期(OS)为19.2个月。ClaPd是RRMM的有效联合方案,缓解和生存结局与来那度胺或硼替佐米难治状态无关,毒性可管理。

要点

  • ClaPd方案治疗RRMM的ORR为60%,23%达到至少非常好的部分缓解。
  • 中位PFS为7.7个月,中位OS为19.2个月。
  • 来那度胺或硼替佐米难治状态不影响缓解率和生存结局。

核心结论

  • ClaPd是RRMM的有效联合方案,缓解和生存结局与来那度胺或硼替佐米难治状态无关,毒性可管理,非血液学或高级别事件发生率低,是便捷的全口服选择,疗效与其他高活性含泊马度胺的三药联合方案相当。

研究设计与样本

  • 该研究为2期试验,纳入120例既往来那度胺暴露的复发或难治性多发性骨髓瘤患者,中位既往治疗线数为5线,治疗方案为克拉霉素500 mg口服每日两次、泊马度胺4 mg口服第1至21天、地塞米松40 mg口服第1、8、15、22天,28天为一周期。

主要发现

  • 总体缓解率(ORR)为60%,23%达到至少非常好的部分缓解。
  • 对来那度胺难治患者的ORR为58%,对硼替佐米难治患者的ORR为55%,对来那度胺和硼替佐米双重难治患者的ORR为54%,各组缓解率无统计学差异。
  • 中位无进展生存期(PFS)为7.7个月,中位总生存期(OS)为19.2个月。
  • 对来那度胺和硼替佐米双重难治史对PFS或OS均无显著影响。
  • 最常见毒性为中性粒细胞减少(83%)、淋巴细胞减少(74%)和血小板减少(71%);最常见的≥3级毒性包括中性粒细胞减少(58%)、血小板减少(31%)和贫血(28%)。

关键数值与推荐

  • 克拉霉素500 mg口服每日两次,泊马度胺4 mg口服第1至21天,地塞米松40 mg口服第1、8、15、22天,28天为一周期。

临床怎么用

  • ClaPd是RRMM的便捷全口服选择,疗效与其他高活性含泊马度胺的三药联合方案相当,毒性可管理。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The addition of clarithromycin enhances the efficacy of lenalidomide plus dexamethasone in treatment-naive multiple myeloma (MM). We conducted a phase 2 trial to evaluate the safety and efficacy of clarithromycin, pomalidomide, and dexamethasone (ClaPd) in relapsed or refractory multiple myeloma (RRMM) with prior lenalidomide exposure. One hundred twenty patients with a median of 5 prior lines of therapy received clarithromycin 500 mg orally twice daily, pomalidomide 4 mg orally on days 1 to 21, and dexamethasone 40 mg orally on days 1, 8, 15, and 22 of a 28-day cycle. The overall response rate (ORR) was 60% with 23% achieving at least a very good partial response. There was no statistical difference in response rates for patients who were refractory to lenalidomide (ORR, 58%), bortezomib (ORR, 55%), or both lenalidomide and bortezomib (ORR, 54%). Median progression-free survival (PFS) for the cohort was 7.7 months and median overall survival (OS) was 19.2 months. A history of dual-refractoriness to lenalidomide and bortezomib did not significantly impact either PFS or OS. The most common toxicities were neutropenia (83%), lymphopenia (74%), and thrombocytopenia (71%). The most common grade ≥3 toxicities included neutropenia (58%), thrombocytopenia (31%), and anemia (28%). ClaPd is an effective combination in RRMM with response and survival outcomes that are independent of lenalidomide- or bortezomib-refractory status. Toxicities are manageable with low rates of nonhematologic or high-grade events. ClaPd is a convenient, all-oral option in RRMM with comparable efficacy to other highly active, 3-drug, pomalidomide-based combinations. This trial was registered at www.clinicaltrials.gov as #NCT01159574.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Mark TM, Forsberg PA, Rossi AC, et al. Phase 2 study of clarithromycin, pomalidomide, and dexamethasone in relapsed or refractory multiple myeloma. Blood Adv. 2019. PMID: 30792190. doi:10.1182/bloodadvances.2018028027

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。